BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
©The Author(s) 2026.
World J Gastroenterol. Feb 7, 2026; 32(5): 116007
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.116007
Table 3 Clinical efficacy analysis, n (%)
SubgroupEfficacy (no stratification)
Efficacy (grade I)
Efficacy (grade II-III)
Cured
Improved
Ineffective
Cured
Improved
Ineffective
Cured
Improved
Ineffective
ERBL40 (57.14)21 (30.00)9 (12.86)16 (72.73)5 (22.73)1 (4.54)24 (50.00)16 (33.33)8 (16.67)
IS27 (40.91)33 (50.00)6 (9.09)15 (60.00)8 (32.00)2 (8.00)12 (29.27)25 (60.97)4 (9.76)
ESB32 (49.23)27 (41.54)6 (9.23)11 (78.57)2 (14.29)1 (7.14)21 (41.18)25 (49.02)5 (9.80)
Total99 (49.25)81 (40.30)21 (10.45)42 (68.85)15 (24.59)4 (6.56)57 (40.72)66 (47.14)17 (12.14)
StatisticH = 1.999H = 1.527H = 1.682
P value0.3680.4660.431


Write to the Help Desk